Shamburg News · 8-K filed Oct 22, 2026, 4:17 PM EDT
Aardvark Therapeutics Says FDA Lifted Clinical Hold on ARD-101 for Prader-Willi Syndrome
AARD · Aardvark Therapeutics, Inc.
- Other event
- Reg FD disclosure
- Materiality: high
Aardvark Therapeutics, Inc. announced that the U.S. Food and Drug Administration lifted the clinical hold on the Company's Investigational New Drug application for ARD-101 for hyperphagia in Prader-Willi Syndrome. The hold had followed a voluntary dosing pause in the Phase 3 HERO trial and its open-label extension in February 2026 after reversible ECG changes, and the Company plans to resume clinical development pending further FDA alignment on the Phase 3 trial design. The Company also scheduled a live investor conference call and webcast for October 23, 2026 at 8:00 a.m. ET to discuss data from the terminated HERO and OLE trials.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-428943.
Written from the filing by Shamburg Markets. Figures are as reported by the company.